Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

revlimid_celgene

Celgene threatens to scale back UK clinical trial investment after CDF snub

September 4, 2015 Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs

One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …
News

Genentech Haemophilia therapy gets FDA breakthrough designation

September 4, 2015 Research and Development, Sales and Marketing Genentech, Roche, haemophilia a

Roche subsidiary Genentech has been granted FDA breakthrough therapy designation for its ACE910 (RG6013, RO5534262) haemophilia A therapy. The designation …
News
cells

How ‘deep reading’ of the scientific literature will benefit pharma

September 3, 2015 Research and Development Big Data, Cancer, Data Mining, R&D, literature search, oncology

The US Defense Advanced Research Projects Agency (DARPA)’s $45 million ‘Big Mechanism’ initiative has an ambitious aim.It promises to “leapfrog …
Feature
dun___bradstreet_4efa511357b57

Shire appoints Sara Mathew to board of directors

September 2, 2015 Manufacturing and Production, Research and Development, Sales and Marketing Sara Mathew, Shire

Shire has appointed Sara Mathew to its board of directors as a non-executive director.Mathew will also be a member of …
Appointment
Alzheimer's brain

Amgen and Novartis partner on Alzheimer’s and migraine treatments

September 2, 2015 Research and Development Alzheimer's disease, Amgen, Novartis, migraine, neurology, neuroscience

Amgen and Novartis have announced a global collaboration to develop neuroscience treatments in Alzheimer’s disease and migraine.  The companies plan …
News
Novartis image

Two Novartis drugs get first in class EU approvals

September 2, 2015 Research and Development, Sales and Marketing Novartis

The European Commission has approved Revolade for severe aplastic anaemia, and the combination of Tafinlar and Mekinist for patients with …
News
Xarelto

Bayer backs safety of Xarelto after real-world data study

September 2, 2015 Research and Development Bayer, ESC, European Society of Cardiology, Xarelto, anticoagulants, atrial fibrillation, real-word evidence, rivaroxaban

Around 96 in every 100 people treated with Bayer’s anticoagulant Xarelto do not experience any major bleeding, related side effects …
News
scales

Standardising the pharma benefit-risk assessment process

September 1, 2015 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, FDA, benefit-risk analysis, pharmacoepidemiology, pharmacovigilance

Over the past decade, pharmaceutical companies and regulatory agencies have been reviewing the benefit-risk assessment of medicines with a view …
Feature
mytrus_cartoon

NHS approves electronic consent technology in clinical trials

August 28, 2015 Medical Communications, Research and Development Mytrus, NHS, clinical trials, digital health technology, electronic informed consent

Clinical technology and services company Mytrus has announced that its software platform for electronic informed consent has received approval for …
News
boehringer_lilly

New Boehringer and Lilly type 2 diabetes treatment gets FDA nod

August 28, 2015 Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, Synjardy, type 2 diabetes

The FDA has approved Synjardy, from Boehringer Ingelheim and Eli Lilly, for the treatment of adults with type 2 diabetes. …
News

FDA approves Amgen’s cholesterol lowering drug

August 28, 2015 Medical Communications, Research and Development Amgen, FDA, Repatha, evolocumab

The FDA has endorsed Amgen’s cholesterol-lowering medication, Repatha, for the use in patients with high cholesterol. It follows Amgen’s successful …
News
ESC congress sign

NHS looks to ESC for next-gen heart drug data

August 28, 2015 Medical Communications, Research and Development ALN-PCScs, Repatha, alirocumab, cardiology, cardiovascular disease, cvd, evolocumab, heart disease, high cholesterol, praluent

New data is expected to be presented at the European Cardiology Society congress in London, on the high cholesterol drugs …
News

Novo Nordisk to buy two pharma research companies

August 27, 2015 Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, mergers and acquisitions

Novo Nordisk is to acquire two privately-held biopharmaceutical research companies specialising in diabetes, for undisclosed sums. Calibrium and MB2, formed …
News
md_anderson_cancer_center

Immatics and MD Anderson launch new company to develop ACR therapies

August 27, 2015 Research and Development, Sales and Marketing Cancer, MD Anderson Cancer Center, immatics, keytruda

Immatics Biotechnologies and The University of Texas MD Anderson Cancer Center (MDACC) have together launched a new company focusing on …
News
alimta

Lilly defeats Teva in US court over Alimta patent

August 26, 2015 Research and Development, Sales and Marketing Alimta, Eli Lilly, Teva Pharmaceutical, lung cancer

Eli Lilly has won a case in a US federal court, in a battle over Teva’s attempt to create a …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026